本页面由Tiger Trade Technology Pte. Ltd.提供服务

再鼎医药

24.79
-0.2050-0.82%
成交量:21.92万
成交额:544.21万
市值:27.85亿
市盈率:-14.55
高:25.00
开:24.88
低:24.51
收:24.99
52周最高:32.76
52周最低:15.96
股本:1.12亿
流通股本:9,711.04万
量比:0.96
换手率:0.23%
股息:- -
股息率:- -
每股收益(TTM):-1.7030
每股收益(LYR):-1.6026
净资产收益率:-26.91%
总资产收益率:-14.75%
市净率:4.59
市盈率(LYR):-15.47

数据加载中...

2026/08/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/12

关联方拟减持公告

Form 144 | Zai Lab Ltd董事 William Lis 计划减持8506股,总价约$212650
2026/08/11

关联方拟减持公告

Form 144 | Zai Lab Ltd 高管 Chen Yajing 拟减持619股,市值约15475美元
2026/08/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/06

重要事件披露

Form 8-K - Current report
2026/06/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/18

重要事件披露

Form 8-K - Current report
2026/06/11

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/21

重要事件披露

Form 8-K - Current report
2026/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]